2020 Vol. 17, No. 8
Intermediate- and high-risk pulmonary embolism (PE) is a life-threatening medical emergency with high morbidity and mortality. Many of the treatment options for PE involve clinicians from multiple disciplines. Pulmonary Embolism Response Teams (PERTs) have been developed to coordinate the multidisciplinary team of clinicians to streamline the decision making process and develop individualised treatment plans in a timely fashion. The first PERT was established in 2012 and subsequently multiple centres worldwide have introduced this model for the management of intermediate- and high-risk PE. In this review, we evaluate the organisational structure and algorithms of different PERT services and compare data from pre- and post-PERT services to determine the impact of PERT on outcomes. We consider the cost and time implications of this multidisciplinary 24-hour service and suggest areas for further research and review.
Previous studies have shown that nicorandil has a protective effect on cardiomyocytes. However, there is no study to investigate whether perioperative intravenous nicorandil can further reduce the myocardial infarct size in patients with ST-segment elevation myocardial infarction (STEMI) compared to the current standard of percutaneous coronary intervention (PCI) regimen. The CHANGE (China-Admini stration of Nicorandil Group) study is a multicenter, prospective, randomized, double-blind and parallel-controlled clinical study of STEMI patients undergoing primary PCI in China, aiming to evaluate the efficacy and safety of intravenous nicorandil in ameliorating the myocar dial infarct size in STEMI patients undergoing primary PCI and provide evidence-based support for myocardial protection strategies of STEMI patients.